Prediction of DDIs for various CYP3A4 substrate drugs with concomitantly administered rifampicin.

a) Fraction of the drug metabolized by CYP3A4 (fmCYP3A4) and clinical DDI data were taken from the article of Ohno et al. [24].b) Clinical data were obtained from the articles shown with the reference ID (Ref. ID).c) Induction ratio (IR) of CYP3A4 activity was calculated from daily dose and days of administration of rifampicin by using Eqs. 6–8 and 15–17. The values for IR were represented as an average and upper and lower limits when one S.D. for inter-individual variability of CYP3A4 baseline activity was considered.